Description: Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Home Page: www.lonza.com
Muenchensteinerstrasse 38
Basel,
4002
Switzerland
Phone:
41 61 316 81 11
Officers
| Name | Title |
|---|---|
| Dr. Wolfgang Wienand Ph.D. | Chief Executive Officer |
| Mr. Philippe Deecke | Chief Financial Officer |
| Ms. Maria Soler Nunez | Head of Group Operations |
| Mr. Dirk Oehlers | Vice President of Investor Relations |
| Mr. Andreas Bohrer | Group General Counsel & Company Secretary |
| Ms. Kim Harrelson | Head of Ethics & Compliance, ERM and Corporate Responsibility |
| Ms. Victoria Morgan | Head of External Communications |
| Ms. Jennifer Clancy | Senior Director of Global Marketing |
| Dr. Matthias Hofmann | Head of Corporate Environment, Health, Safety & Global Sustainability |
| Mr. Jean-Christophe Hyvert | President of Biologics Division |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 30.2115 |
|---|---|
| Trailing PE: | 64.7059 |
| Price-to-Book MRQ: | 3.9444 |
| Price-to-Sales TTM: | 6.0277 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 17834 |